Prophylaxis in people with haemophilia

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 674-681

  Coppola, Antonio ^a   Franchini, Massimo ^b   Tagliaferri, Annarita ^c  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Bleeding; Children; Haemophilia; Prophylaxis; Quality of life

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA; HUMAN; JOINT FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COAGULANTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; MEDICATION ADHERENCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64849093041     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0483     Document Type: Review

References (75)

1. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl 3): 10-18.
2. Rosendaal G, Lafeber F P. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12 (Suppl 3): 117-121.
3. Nilsson IM, Berntorp E, Löfqvist T, et al. Twentyfive years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
5. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-242.
6. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; Suppl 77: 1-98.
7. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
8. Kreuz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-417.
9. van den Berg HM, Fischer K, Mauser-Bunschoten E P, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-565.
10. Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Haemophilia 2002; 8: 489-490.
11. Yee TT, Beeton K, Griffioen A, et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
12. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylaxis therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl 1): 1-4.
13. den Uijl IEM, Fischer K. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. Thromb Haemost 2008; 99: 965.
14. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-127.
15. Valentino LA. Secondary prophylaxis therapy: what are benefits, limitations and unknown? Haemophilia 2004; 10: 147-157.
16. Ljung R. Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. Haemophilia 2007; 13 (Suppl 2): 1-3.
17. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 3 (Suppl 2): 3-6.
18. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-159.
19. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-1113.
20. Fischer K, van der Bom JG, Mauser-Bunschoten E P, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99: 2337-2341.
21. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006; 2: CD003429.
22. Aronstam A, Arblaster PG, Rainsford SG, et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
23. Aronstam A, Kirk PJ, McHardy, et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977; 30: 65-67.
24. Carlsson M, Berntorp E, Bjorkman S, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
25. Morfini M, Mannucci PM, Mariani G, et al. Evaluation of prophylactic replacement in haemophilia B. Scand J Haematol 1976; 16: 41-47.
26. Mannucci PM. Need for randomized trials in haemophilia. J Thromb Haemost 2006; 4: 501-502.
27. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4: 503-504.
28. The Medical and Scientific Advisory Council of the National Haemophilia Foundation. More on: are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006; 4: 1167-1168.
29. Fischer K, Grobbee DE, van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia 2007; 13: 345-350.
30. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
31. Kilcoyne R F, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003; 9 (Suppl 1): 57-64.
32. Doria AS, Lundin B, Kilcoyne R F, et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia 2005; 11: 245-253.
33. Gringeri A. Prospective controlled study on prophylaxis: an Italian approach. Haemophilia 2003; 9 (Suppl 1): 38-43.
34. Gringeri A, Lundin B, von Mackensen S, et al. A 10-yr, randomized clinical trial on prophylaxis vs. on demand treatment in children with haemophilia A: the E.S.P.R.I.T. study. Haemophilia 2008; 14 (Suppl 2): 99 [Abstract].
35. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13 (Suppl 2): 16-22.
36. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well in the presence of inhibitors. Haemophilia 2008; 14 (Suppl 3): 196-201.
37. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous devices in haemophilia. Haemophilia 2004; 10: 134-146.
38. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138: 580-586.
39. Mancuso ME, Mannucci PM, Sartori A, et al. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141: 689-695.
40. Ljung R, Chambost H, Stain AM, Di Michele D. Haemophilia in the first years of life. Haemophilia 2008; 14 (Suppl 3) 188-195.
41. Santagostino E, Mancuso M, Gringeri A, et al. Low-rate of complications after a long-term use of arteriovenous fistula (AVF) in hemophilic children. Haemophilia 2008; 14 (Suppl 2): 99 [Abstract].
42. van den Berg HM, de Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007; 5 (Suppl 1): 151-156.
43. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
44. Feldman BN, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-1236.
45. Spira J, Plyushch O P, Andreeva TA, et al. Prolonged bleeding-free period following prophylactic infusion of recombinant FVIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-3673.
46. Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
47. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-760.
48. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9 (Suppl 1): 27-31.
49. Bohn RL, Schramm W, Bullinger M, et al. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004; 10 (Suppl 1): 2-8.
50. Nicholson A, Berger K, Bohn R, et al. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia 2008; 14: 127-132.
51. Remor E, Young NL, von Mackensen S, Lopatina EG. Disease-specific quality of life measurements tools for haemophilia patients. Haemophilia 2004; 10: 34-41.
52. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.
53. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
54. Brackmann HH, Eickhoff HJ, Oldenburg J, et al. Long-term therapy and on-demand treatment of children and adolescents with severe hemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-258.
55. Manco-Johnson MJ, Nuss R, Geraghty S et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Haematol 1994; 47: 113-117.
56. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-978.
57. Cohen A, White E, Bernstein C, et al. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion 1997; 37: 534-535.
58. Schobess R, Kurnik K, Friedrichs F, et al. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study. Thromb Haemost 2008; 99: 71-76.
59. Hay CRM. Prophylaxis in adults with haemophilia. Haemophilia 2007; 13 (Suppl 2): 10-15.
60. Fischer K, van der Bom JG, Prejs R, et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-550.
61. van Dijk K, Fischer K, van der Bom JG, et al. Can long term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-112.
62. Miners AH, Sabin CA, Tolley KH, et al. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-522.
63. Loverin JA, Mensah P, Nokes TJC. Limited prophylaxis in adults with severe hemophilia: a pilot study. Haemophilia 2000; 6: 274-275 [Abstract].
64. Saba HI, Tannenbaum B, Morelli G, et al. Factor prophylaxis in the management of adult hemophiliacs. Haemophilia 2000; 6: 276-277 [Abstract].
65. Fischer K, Van Dijk K, Van den Berg HM. Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood. J Thromb Haemost 2005; 3 (Suppl 1): OR205 [Abstract].
66. Coppola A, Cimino E, Macarone Palmieri N, et al. Clinical and pharmacoeconomic impact of secondary prophylaxis in young-adults with severe hemophilia A. J Thromb Haemost 2005; 3 (Suppl 1): P1428 [Abstract].
67. Tagliaferri A, Rivolta G F, Rossetti G, et al. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-543.
68. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in young-adult hemophiliacs. Haemophilia 2008; 14: 945-951.
69. Tagliaferri A, Rivolta G F, Mancuso G, et al. Prophylaxis vs. on-demand therapy through economic report. P.O.T.T.E.R. Study. Haemophilia 2008; 14 (Suppl 2): 102 [Abstract].
70. Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients- a long term follow-up. J Intern Med 1997; 241: 395-400.
71. Fischer K, van der Bom JG, Molho P, et al. Prophylaxis versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-752.
72. Rodriguez-Merchan EC, Hedner U, Heijnen L, et al. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated frompatients without inhibitors to patients with inhibitors? Haemophilia 2008; 14 (Suppl 6): 68-81.
73. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-440.
74. Risebrough N, Oh P, Blanchette V, et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743-752.
75. National Hemophilia Foundation. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 179. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx? menuid=57&contentid=1007 (last accessed on 16 July 2008).